Cargando…

Treatment strategy of EGFR-mutated non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Tanaka, Fumihiro, Yoneda, Kazue, Takenaka, Masaru, Kuroda, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987836/ https://www.ncbi.nlm.nih.gov/pubmed/35399242 http://dx.doi.org/10.21037/jtd-22-177

Ejemplares similares

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

CD155 expression and its clinical significance in non-small cell lung cancer
por: Oyama, Rintaro, et al.
Publicado: (2022)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy
por: Mori, Masataka, et al.
Publicado: (2023)

Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer
por: Nawashiro, Ayako, et al.
Publicado: (2022)

Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma
por: Kanayama, Masatoshi, et al.
Publicado: (2021)

Circulating Tumor Cells as an Indicator of Postoperative Lung Cancer: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Prognostic impact of circulating tumor cells detected with the microfluidic “universal CTC‐chip” for primary lung cancer
por: Kanayama, Masatoshi, et al.
Publicado: (2022)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?
por: Bieńkowski, Michał, et al.
Publicado: (2022)

Successful lung-sparing resection of synchronous pleural mesothelioma and contralateral lung cancer
por: Imanishi, Naoko, et al.
Publicado: (2017)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?
por: Takenaka, Tomoyoshi, et al.
Publicado: (2023)

Pulmonary artery reconstruction using autologous pulmonary vein for surgical treatment of locally advanced lung cancer: a case report
por: Hirai, Ayako, et al.
Publicado: (2016)

Mediastinal Tracheostoma for Treatment of Tracheostenosis after Tracheostomy in a Patient with Mucopolysaccharidosis-Induced Tracheomalacia
por: Chikaishi, Yasuhiro, et al.
Publicado: (2017)

Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma
por: Yoneda, Kazue, et al.
Publicado: (2019)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients
por: Shoji, Fumihiro
Publicado: (2020)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
por: Fu, Kai, et al.
Publicado: (2022)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung
por: Tashima, Yuko, et al.
Publicado: (2020)

Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer
por: Hanagiri, Takeshi, et al.
Publicado: (2011)

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
por: Isla, D., et al.
Publicado: (2020)

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2022)

Salvage surgery combined with descending aorta resection for lung cancer
por: Kanayama, Masatoshi, et al.
Publicado: (2019)

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
por: INOUE, Akira
Publicado: (2020)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
por: Yoneda, Kazue, et al.
Publicado: (2019)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities
por: La Monica, Silvia
Publicado: (2022)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jicn15fqt7j0187e1sg06ftuaq